Switch theme
Sign up to access all valuation multiples
Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinson’s disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.
2014
11
LTM Revenue $11K
LTM EBITDA -$5.2M
$34.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Herantis Pharma has a last 12-month revenue (LTM) of $11K and a last 12-month EBITDA of -$5.2M.
In the most recent fiscal year, Herantis Pharma achieved revenue of n/a and an EBITDA of -$5.5M.
Herantis Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Herantis Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $11K | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $11K | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$5.2M | XXX | -$5.5M | XXX | XXX | XXX |
| EBITDA Margin | -46327% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$5.2M | XXX | -$5.6M | XXX | XXX | XXX |
| EBIT Margin | -46327% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | n/a | XXX | -$5.5M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Herantis Pharma's stock price is EUR 1 (or $2).
Herantis Pharma has current market cap of EUR 32.8M (or $36.8M), and EV of EUR 30.6M (or $34.4M).
See Herantis Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $34.4M | $36.8M | XXX | XXX | XXX | XXX | $-0.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Herantis Pharma has market cap of $36.8M and EV of $34.4M.
Herantis Pharma's trades at n/a EV/Revenue multiple, and -6.2x EV/EBITDA.
Equity research analysts estimate Herantis Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Herantis Pharma's P/E ratio is not available.
See valuation multiples for Herantis Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $36.8M | XXX | $36.8M | XXX | XXX | XXX |
| EV (current) | $34.4M | XXX | $34.4M | XXX | XXX | XXX |
| EV/Revenue | 3064.5x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -6.6x | XXX | -6.2x | XXX | XXX | XXX |
| EV/EBIT | -6.6x | XXX | -6.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3064.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -6.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHerantis Pharma's last 12 month revenue growth is n/a
Herantis Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.5M for the same period.
Herantis Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Herantis Pharma's rule of X is -46327% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Herantis Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -46327% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -5% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -46327% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Herantis Pharma acquired XXX companies to date.
Last acquisition by Herantis Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Herantis Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Herantis Pharma founded? | Herantis Pharma was founded in 2014. |
| Where is Herantis Pharma headquartered? | Herantis Pharma is headquartered in Finland. |
| How many employees does Herantis Pharma have? | As of today, Herantis Pharma has 11 employees. |
| Is Herantis Pharma publicy listed? | Yes, Herantis Pharma is a public company listed on HEL. |
| What is the stock symbol of Herantis Pharma? | Herantis Pharma trades under HRTIS ticker. |
| When did Herantis Pharma go public? | Herantis Pharma went public in 2014. |
| Who are competitors of Herantis Pharma? | Similar companies to Herantis Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Herantis Pharma? | Herantis Pharma's current market cap is $36.8M |
| What is the current revenue of Herantis Pharma? | Herantis Pharma's last 12 months revenue is $11K. |
| What is the current EV/Revenue multiple of Herantis Pharma? | Current revenue multiple of Herantis Pharma is 3064.5x. |
| Is Herantis Pharma profitable? | Yes, Herantis Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Herantis Pharma? | Herantis Pharma's last 12 months EBITDA is -$5.2M. |
| What is Herantis Pharma's EBITDA margin? | Herantis Pharma's last 12 months EBITDA margin is -46327%. |
| What is the current EV/EBITDA multiple of Herantis Pharma? | Current EBITDA multiple of Herantis Pharma is -6.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
